The Insanity of the Hepatitis B Vaccination
Conclusions The hepatitis B vaccination program targeting newborns and infants does NOT make sense. The vaccination itself has not proven to be effective in preventing hepatitis B. There is very little risk of children becoming infected with hepatitis B. Hepatitis B is a disease that is not highly infectious and tends to affect adults in high risk groups. The course of the disease is usually self-limiting with lifelong immunity acquired. In contrast, many serious health consequences have resulted from the hepatitis B vaccination, including permanent disability and death. References http://www.nvic.org/nvic-archives/newsletter/untoldstory.aspx http://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#D4 http://www.nvic.org/nvic-archives/newsletter/untoldstory.aspx http://www.immunize.org/catg.d/p2130.pdf http://www.cdc.gov/hepatitis/hbv/vaccchildren.htm http://www.cdc.gov/vaccines/schedules/downloads… http://www.nvic.org/nvic-archives/newsletter/untoldstory.aspx https://vactruth.com/2014/12/12/10-reasons-not-to-vaccinate/ https://vactruth.com/2016/02/18/mmr-vaccine/ http://www.nvic.org/nvic-archives/newsletter/untoldstory.aspx http://www.nvic.org/nvic-archives/newsletter/untoldstory.aspx http://articles.mercola.com/sites/articles/archive… About the Author: Michelle Goldstein is a mental health therapist who is passionate about holistic health, natural healing, nutrient-dense foods and the politics that impact them. She has published articles for Natural News, Vac...
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: Meta GeneAuthor(s): Mansour Zamanpoor, Hamid Ghaedi, Mir Davood Omrani
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Ibironke W. Apata, Sarah Kabbani, Alicia M. Neu, Tamara M. Kear, Erika M.C. D’Agata, David J. Levenson, Alan S. Kliger, Lauri A. Hicks, Priti R. Patel, authors constitute the ASN and CDC Antibiotic Stewardship White Paper Writing Group
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Publication date: December 2020Source: Journal of Functional Foods, Volume 75Author(s): Tingting Wang, Lin Zheng, Tiantian Zhao, Qi Zhang, Zhitong Liu, Xiaoling Liu, Mouming Zhao
Publication date: Available online 9 October 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Brenda Bertado-Cortés, Claudia Venzor-Mendoza, Daniel Rubio-Ordoñez, José Renán Pérez-Pérez, Lucy Andrea Novelo-Manzano, Lyda Viviana Villamil-Osorio, María de Jesús Jiménez-Ortega, María de la Luz Villalpando-Gueich, Nayeli Alejandra Sánchez-Rosales, Verónica García-Talavera
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): G. Alvarez Bravo, L. RamióTorrentà
More News: Academies | Arthritis | Autism | Autoimmune Disease | Babies | Brain | Child Abuse | Child Development | Children | Chronic Pain | Cough | Diabetes | Dialysis | Disability | Encephalitis | Endocrinology | Gammagard Liquid | Guillain-Barr Syndrome | Headache | Health | Health Management | Health Medicine & Bioethics Commentators | Hemodialysis | Hepatitis | Hepatitis B | Hepatitis Vaccine | Jaundice | Liver | Liver Disease | Lupus | Measles | Measles Vaccine | Men | Migraine | Multiple Sclerosis | Mumps | Mumps Vaccine | Neurology | Neuroscience | Nutrition | OBGYN | Occupational Health | Outbreaks | Pain | Pancreatitis | Pediatrics | Politics | Privigen | Rheumatoid Arthritis | Rheumatology | Skin | Statistics | Study | Sudden Infant Death Syndrome | Urology & Nephrology | Vaccines | Websites